Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis

Author:

Goyal Aman1,Abbasi Fatima Qayyum2,Tariq Muhammad Daoud3,Kanagala Sai Gautham4,Changez Mah I. Kan5,Safi Darsh1,Basit Jawad6,Sulaiman Samia Aziz7,Marsool Mohammed Dheyaa Marsool8,Daoud Mohamed9,Sohail Amir H.10

Affiliation:

1. Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India

2. Federal Medical College

3. Foundation University Medical College, Islamabad

4. Department of Internal Medicine, Metropolitan Hospital Center, New York, NY

5. Department of Surgery, Quetta Institute of Medical Sciences, Quetta

6. Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi

7. Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan

8. Department of Internal Medicine, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq

9. Department of Internal Medicine, Bogomolets National Medical University, Kyiv, Ukraine

10. Department of Surgery, University of New Mexico Health Sciences, Albuqurque, NM

Abstract

Background: Recent guidelines suggest that antiplatelet therapy (APT) is the standard of care in the absence of long-term oral anticoagulation (OAC) indications in patients post-transcatheter aortic valve replacement (TAVR). The superiority of one method over the other remains controversial. Materials and methods: Several databases, including MEDLINE, Google Scholar, and EMBASE, were electronically searched. The primary endpoint was the all-cause mortality (ACM) rate. Secondary endpoints included cardiovascular death, myocardial infarction (MI), stroke/TIA, haemorrhagic stroke, bleeding events, systemic embolism, and valve thrombosis in post-TAVR patients receiving APT and oral anticoagulants (OACs). Forest plots were generated using Review Manager version 5.4, with a p value less than 0.05 indicating statistical significance. Subgroup analysis was performed to explore potential sources of heterogeneity. Results: Twelve studies were selected. No significant differences were observed in APT and OAC group for ACM [risk ratio (RR): 0.67; 95% CI:0.45–1.01; P=0.05], cardiovascular death [RR:0.91; 95% CI:0.73–1.14; P=0.42], MI [RR:1.69; 95% CI:0.43–6.72; P=0.46], Stroke/TIA [RR:0.79; 95% CI:0.58–1.06; P=0.12], ischaemic stroke [RR:0.83; 95% CI:0.50–1.37; P=0.47], haemorrhagic stroke [RR:1.08; 95% CI: 0.23–5.15; P=0.92], major bleeding [RR:0.79; 95% CI:0.51–1.21; P=0.28], minor bleeding [RR:1.09; 95% CI: 0.80–1.47; P=0.58], life-threatening bleeding [RR:0.85; 95% CI:0.55–1.30; P=0.45], any bleeding [RR:0.98; 95% CI:0.83–1.15; P=0.78], and systemic embolism [RR:0.87; 95% CI:0.44–1.70; P=0.68]. The risk of valve thrombosis was higher in patients receiving APT than in those receiving OAC [RR:2.61; 95% CI:1.56–4.36; P =0.0002]. Conclusions: Although the risk of valve thrombosis increased in patients receiving APT, the risk of other endpoints was comparable between the two groups.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference30 articles.

1. Treating symptomatic aortic stenosis with transcatheter aortic valve replacement: is there time to wait?;Faridi;JAMA Cardiol,2018

2. Trends in surgical aortic valve replacement in pre- and post-transcatheter aortic valve replacement eras at a structural heart center;Norton;Front Cardiovasc Med,2023

3. Vascular complications in TAVR: incidence, clinical impact, and management;Mach;J Clin Med,2021

4. The “Big Five” complications after transcatheter aortic valve replacement;Grube;JACC Cardiovasc Interv,2019

5. Duration of antiplatelet therapy following transcatheter aortic valve replacement: systematic review and network meta-analysis;Kuno;JAMA Cardiol,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3